Synonyms
- B*51:01
- B51
- Behcet
- Behcet Disease
- Behcet's Disease
- HLA B*51:01
- HLA B51
Special Instructions
If you have questions, please call 800-533-1037 (HLA customer service) for assistance in selecting the proper HLA test for the patient.
Expected Turnaround Time
3 - 7 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
Specimen Requirements
Specimen
Whole blood
Volume
7 mL
Minimum Volume
3 mL
Container
Lavender-top (EDTA) tube
Storage Instructions
Maintain specimen at room temperature; protect from extreme heat or cold. Do not freeze.
Causes for Rejection
Hemolyzed specimen; clotted specimen; wrong specimen container
Test Details
Use
Behcet Disease (BD) is a rare, chronic, multisystem disease caused by vasculitis of blood vessels throughout the body. The disease course is marked by recurrent ulcers of the oral and genital regions, often with severe ocular inflammation that may lead to visual impairment or blindness. This disease is found most often in individuals that carry the HLA B*51 allele of the major histocompatibily complex (MHC). HLA B*51 is the predominant risk factor for BD in all populations studied, however not all BD patients carry the B*51 allele. The disease is prevalent in countries in the eastern Mediterranean, the Middle East, and East Asia and in individuals of Middle Eastern, Far Eastern and Mediterranean decent.
Limitations
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Methodology
Sequence-based typing (SBT), sequence-specific oligonucleotide probes (SSOP), and/or sequence-specific primers (SSP) as needed to obtain the required resolution.
References
Ombrello MJ, Kirino Y, de Bakker PI, Gül A, Kastner DL, Remmers EF. Behcet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci USA. 2014 Jun 17;111(24):8867-8872.24821759
Verity DH, Wallace GR, Vaughan RW, Stanford MR. Behcet's disease: From Hippocrates to the third millennium. Br J Ophthalmol. 2003 Sep;87(9):1175-1183.12928293
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 167389 | HLA B*51 Disease Association | 13299-3 | 167729 | HLA-B | 13299-3 | |
| 167389 | HLA B*51 Disease Association | 13299-3 | 167730 | HLA-B | 13299-3 | |
| 167389 | HLA B*51 Disease Association | 13299-3 | 167384 | HLA Methodology | 49549-9 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf